A. Lai

发表

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer

K. Bromberg, R. Johnstone, C. Kearney, 2022, Clinical epigenetics.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

Antoine de Weck, Joshua M. Korn, Eric Billy, 2017, Cell.

Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.

Mikkel A. Algire, K. Bromberg, M. Michaelides, 2021, Bioorganic & medicinal chemistry letters.

RBP1 Recruits the mSIN3-Histone Deacetylase Complex to the Pocket of Retinoblastoma Tumor Suppressor Family Proteins Found in Limited Discrete Regions of the Nucleus at Growth Arrest

D. Reinberg, B. Kennedy, William Arbuthnot Sir Lane, 2001, Molecular and Cellular Biology.

Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors.

D. Bussiere, Yipin Lu, Li Zhang, 2017, Journal of molecular biology.

RBP1 induces growth arrest by repression of E2F-dependent transcription

P. Branton, R. Marcellus, A. Lai, 1999, Oncogene.

Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells

P. Branton, E. Querido, J. G. Teodoro, 1997, Journal of virology.

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Konstantinos J. Mavrakis, John A. Tallarico, W. Sellers, 2016, Science.

Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome

J. Brickman, K. Bromberg, Chunaram Choudhary, 2018, Cell.

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.

Jafar S. Jabbari, J. Licht, D. Landau, 2021, Molecular cell.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

J. Llovet, A. Zhu, J. Avruch, 2015, Cell reports.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Chunaram Choudhary, Saul H. Rosenberg, Ronen Marmorstein, 2017, Nature.

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

J. Langston, K. Bromberg, M. Michaelides, 2017, ACS medicinal chemistry letters.

The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.

Ryan A McClure, K. Longenecker, Chaohong Sun, 2022, ACS chemical biology.

Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity

Mark Isalan, Michael Moore, Philip D. Gregory, 2003, Proceedings of the National Academy of Sciences of the United States of America.

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

W. Sellers, T. Roberts, F. Hofmann, 2012, PloS one.

Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP

L. Lam, Xin Lu, T. Uziel, 2018, Molecular Cancer Therapeutics.

Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.

Mikkel A. Algire, Chaohong Sun, K. Bromberg, 2021, ACS medicinal chemistry letters.

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo.

Mikkel A. Algire, Chaohong Sun, J. Randolph, 2023, Journal of medicinal chemistry.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Mikkel A. Algire, L. Lam, Chaohong Sun, 2017, Nature.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

J. Llovet, A. Zhu, J. Avruch, 2015, Cell reports.